List of Excipients in Branded Drug NIFEDICAL

« Back to Dashboard

Generic Drugs Containing NIFEDICAL

Company	Ingredient	NDC	Excipient
State of Florida DOH Central Pharmacy	nifedipine	53808-0851	ANHYDROUS LACTOSE
State of Florida DOH Central Pharmacy	nifedipine	53808-0851	CELLULOSE, MICROCRYSTALLINE
State of Florida DOH Central Pharmacy	nifedipine	53808-0851	COLLOIDAL SILICON DIOXIDE
State of Florida DOH Central Pharmacy	nifedipine	53808-0851	ETHYLCELLULOSES
State of Florida DOH Central Pharmacy	nifedipine	53808-0851	FERRIC OXIDE RED
State of Florida DOH Central Pharmacy	nifedipine	53808-0851	HYDROXYETHYL CELLULOSE

What are the Most Frequently-Used Excipients in NIFEDICAL?

# Of NDCs	Excipient
2	ANHYDROUS LACTOSE
2	CELLULOSE, MICROCRYSTALLINE
1	COLLOIDAL SILICON DIOXIDE
1	ETHYLCELLULOSE
1	ETHYLCELLULOSES
2	FERRIC OXIDE RED

Nifedical Excipient Strategy and Commercial Opportunities

Last updated: September 27, 2026

Nifedical XL is an extended-release nifedipine product used for hypertension and chronic stable angina. Its commercial value is no longer driven by compound exclusivity. The opportunity is in reliable controlled release, bioequivalence performance, supply continuity, differentiated packaging, and lower-cost manufacturing.

The strongest excipient strategy uses a robust hydrophilic matrix or equivalent extended-release platform, limits unnecessary formulation complexity, controls photodegradation, and manages lactose, surfactant, and coating-material sensitivities. Nifedipine is an old small-molecule drug with no biosimilar barrier and limited patent protection. Competition is primarily generic and manufacturing-based.

What formulation does Nifedical XL use?

Nifedical XL is a once-daily, extended-release tablet containing nifedipine. Public product information identifies the dosage form as a film-coated extended-release tablet. The product is available in multiple strengths, generally including 30 mg, 60 mg, and 90 mg presentations, depending on the marketed product and supplier.

The product’s formulation objectives are:

• Maintain a controlled nifedipine release profile over approximately 24 hours.
• Avoid dose dumping after alcohol exposure or abnormal gastrointestinal transit.
• Protect nifedipine from light.
• Deliver reproducible exposure despite nifedipine’s low aqueous solubility.
• Preserve tablet integrity during manufacturing, packaging, shipping, and patient handling.

Nifedipine is poorly water-soluble and highly sensitive to light. These properties make dissolution control and packaging material selection more important than the simple tablet weight or ingredient count.

What excipients are used in Nifedical XL?

Public labeling for nifedipine extended-release products identifies excipient classes that can include:

Excipient class	Typical function in the product
Hypromellose	Hydrophilic matrix former or release-controlling polymer
Lactose monohydrate	Diluent and tablet bulking agent
Povidone	Binder and granulation aid
Magnesium stearate	Lubricant
Polyethylene glycol	Film-coating plasticizer
Talc	Anti-tacking and coating aid
Titanium dioxide	Opacifier and light-protection aid
Sodium lauryl sulfate	Wetting or dissolution-support agent in some formulations

The exact qualitative and quantitative composition depends on the manufacturer and approved product version. The formulation cannot be treated as interchangeable with another nifedipine extended-release product without comparative dissolution and bioequivalence evidence.

How should an excipient strategy for Nifedical be designed?

The preferred development strategy is to separate the formulation into four control problems: release control, solubility management, light protection, and manufacturing robustness.

Release-controlling matrix

Hypromellose is commercially attractive because it is widely available, scalable, and compatible with direct compression or wet granulation. Its hydration rate, viscosity grade, particle size, and concentration can materially affect nifedipine release.

Key development variables include:

• Polymer viscosity grade.
• Polymer concentration.
• Tablet porosity.
• Drug particle size.
• Compression force.
• Granulation endpoint.
• Lubrication time.
• Coating weight.

A matrix formulation should be tested under pH conditions representing the stomach and intestine. Testing should include agitation-rate sensitivity and alcohol-challenge conditions where required by the applicable FDA guidance and product-specific expectations.

Solubility and wetting control

Nifedipine’s low water solubility can create a risk that dissolution results reflect drug particle properties rather than the intended matrix design. Particle-size control, micronization, wetting agents, and dispersion quality can reduce batch variability.

Sodium lauryl sulfate can improve wetting but introduces a tolerability and regulatory tradeoff. Excess surfactant may alter the release profile, increase gastrointestinal irritation potential, or create unnecessary formulation complexity. Its use should be justified by dissolution performance rather than added as a default excipient.

Light protection

Nifedipine is light sensitive. The formulation should use an opaque film coat, opaque blister, high-barrier bottle, or a combination of these controls. Titanium dioxide can support coating opacity, although packaging selection remains important because the coating alone may not provide sufficient protection during long-term storage.

Commercially relevant packaging options include:

• High-density polyethylene bottles with light-resistant containers.
• Unit-dose aluminum-aluminum blisters.
• Cold-form foil for maximum light and moisture protection.
• Patient-friendly calendar packaging for once-daily adherence.

Packaging may provide a more defensible product differentiation than a minor excipient substitution.

Manufacturing robustness

A commercially viable formulation should tolerate ordinary variation in powder flow, compression force, coating weight, and scale-up conditions. Overly narrow process windows create supply risk and increase the cost of technology transfer.

The most practical platform is generally a matrix tablet with conventional excipients, supported by:

• Narrow nifedipine particle-size specifications.
• Validated blend uniformity controls.
• Dissolution-based in-process monitoring.
• Low-light manufacturing and packaging controls.
• Defined lubrication limits.
• Stability testing under light, heat, and humidity stress.

What commercial opportunities exist for Nifedical excipients?

The commercial opportunity is strongest in generic substitution, contract manufacturing, supply resilience, and product-line expansion rather than new chemical entity protection.

Lower-cost generic manufacture

A formulation using commodity hypromellose, lactose, povidone, magnesium stearate, and standard coating materials can support competitive cost of goods. The main economic risk is not excipient price. It is failed dissolution, batch rejection, or a need for repeated bioequivalence studies after formulation changes.

A low-cost strategy should avoid unnecessary proprietary polymers or complex multiparticulate technologies unless they provide a demonstrated regulatory or performance advantage.

Excipient substitution

Potential substitutions include:

• Mannitol or microcrystalline cellulose for lactose.
• Crospovidone or alternative binders where justified.
• Alternative hydrophilic polymers for hypromellose.
• Sodium stearyl fumarate or another lubricant where magnesium stearate affects release.
• Film-coating systems with different opacifiers or plasticizers.

Substitution opportunities are commercially relevant when they address supply shortages, lactose sensitivity, regional excipient availability, or manufacturing performance. Each change requires comparative dissolution and may require regulatory reporting or a supplement, depending on the approved application and the scale of the change.

Lactose-free positioning

A lactose-free nifedipine extended-release tablet could target patients and prescribers seeking to avoid lactose-containing formulations. The commercial benefit is likely niche because the quantity of lactose in a tablet is generally small and lactose intolerance is not equivalent to milk-protein allergy.

The opportunity is strongest if the lactose-free formulation also offers:

• Comparable or improved dissolution.
• Fewer excipients.
• Better supply continuity.
• Clear labeling.
• Competitive pricing.

A lactose-free claim must be supported by the final composition and applicable labeling requirements.

Alternative dosage forms

Potential adjacent products include:

• Lower-dose tablets for titration.
• Unit-dose packaging.
• Sprinkle or dispersible systems, if clinically and regulatorily supported.
• Hospital-use packaging.
• Modified-release capsules or multiparticulates.
• Combination products for hypertension.

Alternative dosage forms carry higher regulatory risk because a change in release mechanism, administration method, or food interaction can create a new bioequivalence and labeling burden.

What patents protect Nifedical and nifedipine extended-release products?

Nifedical’s principal active ingredient, nifedipine, is an old small molecule. Its basic compound patent and early use patents expired many years ago. The product’s commercial position is therefore not based on remaining compound exclusivity.

No active compound-level exclusivity should be assumed for nifedipine. Any remaining protection would more likely relate to a specific formulation, manufacturing process, device, or packaging configuration rather than nifedipine itself.

What is the Orange Book status of Nifedical?

Nifedical XL is a generic-style extended-release nifedipine product rather than a recently approved innovator medicine with meaningful remaining market exclusivity. Orange Book analysis should distinguish:

1. The reference listed drug for nifedipine extended-release tablets.
2. Any approved ANDA products.
3. Patent certifications associated with a particular application.
4. Whether a formulation patent is listed for the relevant reference product.

For an old nifedipine extended-release product, no meaningful current patent barrier should be presumed without reviewing the FDA Orange Book entry and the applicable product label. The absence of an active listed patent would mean that Paragraph IV litigation is not the principal commercial risk.

When does Nifedical lose exclusivity?

Nifedical has no expected future loss of core exclusivity comparable to a modern branded drug. Nifedipine’s original market exclusivity and compound patent protection expired decades ago.

Exclusivity category	Nifedical assessment
New chemical entity exclusivity	Expired
Original compound patent	Expired
Modern orphan exclusivity	Not applicable
Biologic exclusivity	Not applicable
Biosimilar pathway	Not applicable
Formulation or process protection	Product-specific; requires current patent review
Generic competition	Established

The relevant launch question is therefore whether a new applicant can obtain FDA approval and reliably meet the reference product’s extended-release performance requirements.

Are there Paragraph IV challenges or patent litigation involving Nifedical?

The commercial record for an old nifedipine product is more likely to involve ANDA approvals, product discontinuations, supply changes, and ordinary generic competition than active high-value patent litigation.

No major current Paragraph IV campaign or settlement agreement should be assumed for Nifedical without a current review of FDA litigation records, district-court dockets, and the Orange Book. The lack of a meaningful compound patent estate reduces the probability that litigation will block generic entry.

What patent litigation affects nifedipine extended-release products?

Potential disputes would most likely concern:

• Whether an applicant infringes a listed formulation patent.
• Whether the applicant’s dissolution profile falls within a claimed release mechanism.
• Manufacturing-process claims.
• Labeling carve-outs for method-of-use patents.
• Trade-secret disputes involving manufacturing parameters.

These risks are narrower than those associated with patented controlled-release platforms or branded cardiovascular products with active formulation patents.

What method-of-use patents protect Nifedical?

Nifedipine is used for hypertension and angina, both established indications. Broad method-of-use protection for these indications is unlikely to create a meaningful current barrier because the underlying clinical uses are longstanding.

A method-of-use patent could still matter if it claims:

• A specific dosing regimen.
• A defined patient population.
• A combination with another cardiovascular agent.
• A specific treatment-resistant population.
• A pharmacokinetic or food-related administration method.

For a generic product, a Section viii labeling strategy may be relevant if a still-protected use is carved out. The practical value depends on the scope of the approved label and the commercial importance of the protected indication.

How strong is the Nifedical patent estate?

The patent estate is weak at the active-ingredient level and potentially moderate only where a supplier relies on proprietary formulation or process claims.

Patent factor	Assessment
Active ingredient	Weak; old and off-patent
Broad therapeutic use	Weak; established indications
Extended-release formulation	Potentially relevant but product-specific
Manufacturing process	Moderate if technically narrow and difficult to design around
Packaging and light protection	Usually weak unless tied to a novel system
Generic entry barrier	Low to moderate
Biosimilar barrier	None

The more durable competitive advantage is likely to come from regulatory execution and manufacturing reliability.

What FDA regulatory status applies to Nifedical?

Nifedical XL is regulated as an oral extended-release prescription drug. A new generic applicant would generally pursue an abbreviated new drug application and demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference product.

Regulatory priorities include:

• Strength and dosage-form equivalence.
• Extended-release dissolution matching.
• Bioequivalence under fasting and fed conditions where required.
• Food-effect characterization.
• Alcohol-induced dose-dumping assessment where applicable.
• Stability through the proposed shelf life.
• Adequate control of light exposure.
• Accurate labeling of administration restrictions.

A formulation that uses different excipients may still be approvable, but excipient changes can affect dissolution, absorption, tolerability, and labeling.

What generic launch scenarios exist for Nifedical?

Scenario 1: Commodity matrix generic

This is the lowest-cost path. The applicant uses conventional hydrophilic polymers and standard tableting equipment. The main risk is failure to reproduce the reference dissolution profile.

Scenario 2: Supply-resilient formulation

The applicant develops a formulation with multiple qualified suppliers for the polymer, lubricant, diluent, and coating system. This approach has direct commercial value where shortages or supplier concentration affect existing products.

Scenario 3: Lactose-free product

A lactose-free version may obtain limited differentiation in retail and institutional channels. Its success depends on maintaining equivalent release performance without increasing tablet size or manufacturing cost.

Scenario 4: Premium packaging

Opaque unit-dose blister packaging can support institutional sales and light-protection claims. The incremental packaging cost must be justified by reduced stability risk, adherence benefits, or channel access.

Scenario 5: Authorized or private-label generic

A manufacturer can license or supply the product to a distributor, pharmacy chain, or regional pharmaceutical company. The opportunity depends on manufacturing capacity, ANDA ownership, supply commitments, and channel pricing.

How does Nifedical compare with other calcium-channel blockers?

Nifedical competes with generic extended-release nifedipine and other long-acting dihydropyridine calcium-channel blockers, including amlodipine and felodipine.

Product class	Release and formulation issue	Commercial position
Nifedipine extended release	Strong dependence on dissolution and light protection	Generic, price-sensitive
Amlodipine tablets	Immediate-release active ingredient with long half-life	Simpler formulation and broad generic supply
Felodipine extended release	Modified-release formulation and food considerations	Smaller market and formulation-sensitive
Nifedipine capsules	Immediate-release dosage form	Different clinical and regulatory positioning

Amlodipine generally has a simpler manufacturing proposition because it does not require the same extended-release matrix control. Nifedical can compete where prescribers or formularies specifically prefer nifedipine extended release, but the product has limited ability to command a premium without a clear formulation or supply advantage.

What revenue exposure and licensing opportunities exist?

Revenue exposure is concentrated in unit volume, reimbursement status, and manufacturing cost. Because nifedipine extended-release products are mature generics, price erosion is a central risk.

Commercial opportunities include:

• Licensing an approved ANDA to a regional marketer.
• Contract manufacturing for pharmacy and hospital suppliers.
• Dual sourcing of critical polymers and coating materials.
• Private-label supply.
• Portfolio bundling with other antihypertensive generics.
• Manufacturing transfer to lower-cost facilities.
• Institutional packaging and supply contracts.

Licensing value is higher when the product has an active approval, clean regulatory history, reliable supply, and multiple strengths. A formulation concept without an approved regulatory pathway has limited value unless it produces a clearly superior dissolution profile or solves a documented supply problem.

What manufacturing and intellectual-property barriers remain?

The main barriers are technical rather than patent-based:

• Reproducing the reference extended-release profile.
• Controlling nifedipine particle size and light exposure.
• Maintaining blend uniformity at low drug loading.
• Preventing coating defects.
• Demonstrating stability across climatic zones.
• Avoiding food and alcohol-related release abnormalities.
• Securing qualified suppliers for high-viscosity polymers.
• Managing post-approval changes without disrupting bioequivalence.

These barriers can support a modest competitive moat for a reliable manufacturer, even when no significant patent protection remains.

Key Takeaways

• Nifedical XL is an extended-release nifedipine tablet whose value depends on controlled release, light protection, and supply reliability.
• Hypromellose-based matrix technology is the most practical excipient platform for a cost-efficient generic.
• Lactose, sodium lauryl sulfate, lubricants, and coating materials are the main excipient areas for substitution or differentiation.
• Nifedipine’s compound patent and original exclusivity have expired; biosimilar risk is irrelevant.
• No meaningful patent-based barrier should be presumed without a current Orange Book and litigation review.
• The strongest commercial opportunities are private-label supply, contract manufacturing, authorized generic arrangements, and supply-resilient formulations.
• Premium pricing is unlikely without a differentiated dosage form, packaging system, or documented supply advantage.
• Manufacturing execution and regulatory bioequivalence are more important than broad intellectual-property protection.

FAQs

Can Nifedical XL be reformulated without lactose?

Yes, a lactose-free formulation is technically feasible, but the replacement diluent can alter tablet compression, dissolution, and bioequivalence. The commercial value depends on whether the product maintains equivalent performance at a competitive cost.

Which excipient is most important for Nifedical release control?

Hypromellose is generally the most important release-controlling excipient in a hydrophilic matrix design. Polymer grade, concentration, hydration behavior, and tablet porosity can materially change nifedipine dissolution.

Is nifedipine extended release protected by formulation patents?

Some products may have had formulation or process patents, but nifedipine’s core compound protection is expired. Current protection must be assessed against the specific reference product, Orange Book listings, and active patent claims.

Can an existing nifedipine tablet be converted into a sprinkle product?

Not automatically. A sprinkle product changes administration, particle exposure, release behavior, and potentially food interaction. It would require product-specific development and regulatory support.

Is Nifedical a biosimilar-risk product?

No. Nifedical contains nifedipine, a synthetic small molecule. Competitive risk comes from generic drugs and formulation-equivalent products, not biosimilars.

References

1. U.S. Food and Drug Administration. (n.d.). Nifedical XL: Nifedipine extended-release tablets prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.

3. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2015). Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system.

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.